Association between hyperuricemia and hypertension in chronic kidney disease

doi:10.16150/j.1671-2870.2023.02.009

Abstract

Abstract:

Objective: To investigate the relationship between hyperuricemia and hypertension in patients with chronic kidney disease (CKD). Methods: The demographic characteristics, blood pressure and biochemical indicators in 530 outpatients of CKD were analyzed in this study from Jan 2020 to Mar 2020 in the Nephrology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Multivariate logistic regression analysis was used to evaluate the correlation between serum uric acid and hypertension in CKD patients. Results: The prevalence of hyperuricemia in CKD patients was 42.6%, and the prevalence of hypertension was 60.4%. In patients with CKD from stages 1 to 5, the prevalence of hypertension was 37.3%, 57.4%, 74.0%, 78.8%， 83.6% respectively, and the prevalence of hyperuricemia was 19.5%， 35.7%， 65.4%， 61.5%， 55.2% respectively. The prevalence of both hyperuricemia and hypertension among CKD 1-5 were significantly different. By comparison with the serum uric acid level in the first quartile (Q1，the multivariate-adjusted odds for hypertension in the Q2, Q3 and Q4 were 1.588, 1.368 and 2.542 times respectively. Among them, the risk of hypertension in the highest quartile group was 2.542 times as the risk in Q1. Conclusions: Among CKD patients, there is a significant correlation between hyperuricemia and hypertension. The risk of hypertension increases with the rise of serum uric acid level. More attention should be paid to CKD patients with asymptomatic hyperuricemia.

Key words: Chronic kidney disease, Hyperuricemia, Hypertension

CLC Number:

R692
R544.1

QIAN Ying, MA Xiaobo, GAO Chenni, ZHANG Chunli, MA Jun, ZHANG Wen, CHEN Xiaonong. Association between hyperuricemia and hypertension in chronic kidney disease[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(02): 160-165.

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 35

[1]	HEINE G H, ELLER K, STADLER J T, et al. Lipid-modifying therapy in chronic kidney disease: Pathophysio-logical and clinical considerations[J]. Pharmacol Ther, 2020, 207:107459. doi: 10.1016/j.pharmthera.2019.107459 URL
[2]	陈新田, 鲍苗, 呼延逸然, 等. 慢性肾脏病患者肾组织USP7和自噬相关蛋白的表达及其与肾间质纤维化的关系[J]. 中国临床研究, 2023, 36(7):1027-1032.
	CHEN X T, BAO M, HUYAN Yiran, et al. Expression of USP7 and autophagy-related protein in renal tissue of chronic kidney disease patients and its relationship with renal interstitial fibrosis[J]. Chin J Clin Res, 2023, 36(7):1027-1032.
[3]	O'DONNELL M J, CHIN S L, RANGARAJAN S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study[J]. Lancet, 2016, 388(10046):761-775. doi: 10.1016/S0140-6736(16)30506-2 pmid: 27431356
[4]	郑颖. 慢性肾脏病高血压管理与展望[J]. 中华肾病研究电子杂志, 2022, 11(1):60.
	ZHENG Y. Management and perspectives of hypertension in CKD[J]. Chin J Kidney Dis Invest, 2022, 11(1):60.
[5]	WAHEED Y, YANG F, SUN D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease[J]. Korean J Intern Med, 2021, 36(6):1281-1293. doi: 10.3904/kjim.2020.340 pmid: 33045808
[6]	GHERGHINA M E, PERIDE I, TIGLIS M, et al. Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment[J]. Int J Mol Sci, 2022, 23(6):3188. doi: 10.3390/ijms23063188 URL
[7]	吴芃, 王亮, 李海涛, 等. 高尿酸血症模型的建立及降尿酸药物的研究进展[J]. 中国病理生理杂志, 2021, 37(7):1283-1294.
	WU P, WANG L, LI H T, et al. Progress in hyperuricemia model establishment and uric acid-lowering drugs[J]. Chin J Pathophysiol, 2021, 37(7):1283-1294.
[8]	SAMPSON A L, SINGER R F, WALTERS G D. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease[J]. Cochrane Database Syst Rev, 2017, 10(10):CD009460.
[9]	LI X, MENG X, TIMOFEEVA M, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies[J]. BMJ, 2017, 357:j2376.
[10]	JOHNSON R J, BAKRIS G L, BORGHI C, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation[J]. Am J Kidney Dis, 2018, 71(6):851-865. doi: S0272-6386(18)30087-8 pmid: 29496260
[11]	INKER L A, ENEANYA N D, CORESH J, et al. New creatinine- and cystatin c-based equations to estimate GFR without race[J]. N Engl J Med, 2021, 385(19):1737-1749. doi: 10.1056/NEJMoa2102953 URL
[12]	DELANAYE P, JAGER K J, BÖKENKAMP A, et al. CKD: a call for an age-adapted definition[J]. J Am Soc Nephrol, 2019, 30(10):1785-1805. doi: 10.1681/ASN.2019030238 pmid: 31506289
[13]	EDWARDS N L, SCHLESINGER N, CLARK S, et al. Management of gout in the United States: a claims-based analysis[J]. ACR Open Rheumatol, 2020, 2(3):180-187. doi: 10.1002/acr2.11121 pmid: 32114719
[14]	娄莹, 马文君, 王子君, 等. 中国高血压临床实践指南计划书[J]. 中华心血管病杂志, 2022, 50(7):671-675.
	LOU Y, MA W J, WANG Z J, et al. Writing protocols for the Chinese clinical practice guidelines of hypertension[J]. Chin J Cardiol, 2022, 50(7):671-675.
[15]	张伟丽, 惠汝太. 高尿酸血症和高血压风险:一个新的治疗靶标[J]. 中华医学杂志, 2010, 90(10):712-714.
	ZHANG W L, HUI R T. Hyperuricemia and risk of hypertension: a new treatment target[J]. Natl Med J China, 2010, 90(10):712-714.
[16]	杨潇潇, 李燕, 王继光, 等. 住院青少年高血压患者临床资料分析[J]. 中华高血压杂志, 2011, 19(6):524-528.
	YANG X X, LI Y, WANG J G, et al. Clinical data analysis of hospitalized adolescent patients with hypertension[J]. Chin J Hypertens, 2011, 19(6):524-528.
[17]	杨洋, 龚艳春. 无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展[J]. 内科理论与实践, 2021, 16(5):366-370.
	YANG Y, GONG Y C. Research advances on the relationship between asymptomatic hyperuricemia and cardiovascular and kidney disease[J]. J Intern Med Concepts Pract, 2021, 16(5):366-370.
[18]	CHA R H, KIM S H, BAE E H, et al. Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: a questionnaire survey[J]. Kidney Res Clin Pract, 2019, 38(3):373-381. doi: 10.23876/j.krcp.19.007 URL
[19]	贾世柱, 陈建德, 邵光新. 慢性肾脏病患者高尿酸血症和高血压关系观察[J]. 皖南医学院学报, 2015(3):252-254.
	JIA S Z, CHEN J D, SHAO G X. Hyperuricemia and hypertension in chronic kidney disease[J]. Acta Acad Med Wannan, 2015(3):252-254.
[20]	KAWAZOE M, FUNAKOSHI S, ISHIDA S, et al. Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study[J]. J Clin Hypertens (Greenwich), 2021, 23(12):2071-2077. doi: 10.1111/jch.14390 pmid: 34806282
[21]	EJAZ A A, NAKAGAWA T, KANBAY M, et al. Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage[J]. Semin Nephrol, 2020, 40(6):574-585. doi: 10.1016/j.semnephrol.2020.12.004 pmid: 33678312
[22]	YANG X, GU J, LV H, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor[J]. Biomed Pharmacother, 2019, 109:1163-1170. doi: S0753-3322(18)33454-1 pmid: 30551366
[23]	PIJAK M R. A role for asymptomatic hyperuricemia in the progression of cardiovascular and renal disease[J]. BMJ, 2020, 110(5 Pt 1):2390-2397.
[24]	HISATOME I, LI P, MIAKE J, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular di-sease - Japanese guideline on the management of asymptomatic hyperuricemia[J]. Circ J, 2021, 85(2):130-138. doi: 10.1253/circj.CJ-20-0406 URL
[25]	JUNG S W, KIM S M, KIM Y G, et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(6):F1327-F1340. doi: 10.1152/ajprenal.00272.2019 URL
[26]	PONTICELLI C, PODESTÀ M A, MORONI G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease[J]. Kidney Int, 2020, 98(5):1149-1159. doi: 10.1016/j.kint.2020.05.056 pmid: 32650020
[27]	UEDONO H, TSUDA A, ISHIMURA E, et al. U-shaped relationship between serum uric acid levels and intrarenal hemodynamic parameters in healthy subjects[J]. Am J Physiol Renal Physiol, 2017, 312(6):F992-F997. doi: 10.1152/ajprenal.00645.2016 URL
[28]	SANCHEZ-LOZADA L G, RODRIGUEZ-ITURBE B, KELLEY E E, et al. Uric Acid and Hypertension: An Update With Recommendations[J]. Am J Hypertens, 2020, 33(7):583-594. doi: 10.1093/ajh/hpaa044 URL
[29]	刘沛, 郭威, 王中亮, 等. 基于logistic回归和随机森林的慢性肾脏病危险程度预测模型[J]. 中国卫生统计, 2020, 37(4):514-518.
	LIU P, GUO W, WANG Z L, et al. Multi-classification logistic regression and random forest model on the risk of CKD prediction[J]. Chin J Health Statistics, 2020, 37(4):514-518.
[30]	OMIZO H, TAMURA Y, MORIMOTO C, et al. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia[J]. Sci Rep, 2020, 10(1):9326. doi: 10.1038/s41598-020-65706-6 pmid: 32518351
[31]	BADVE S V, PASCOE E M, TIKU A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease[J]. N Engl J Med, 2020, 382(26):2504-2513. doi: 10.1056/NEJMoa1915833 URL
[32]	PENG Y L, TAIN Y L, LEE C T, et al. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease[J]. Sci Rep, 2020, 10(1):10734. doi: 10.1038/s41598-020-67026-1
[33]	KIELSTEIN J T, PONTREMOLI R, BURNIER M. Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection[J]. Curr Hypertens Rep, 2020, 22(12):102. doi: 10.1007/s11906-020-01116-3 pmid: 33128170
[34]	CHEN Q, WANG Z, ZHOU J, et al. Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis[J]. Clin J Am Soc Nephrol, 2020, 15(11):1576-1586. doi: 10.2215/CJN.05190420 URL
[35]	中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者高血压管理指南(2023年版)[J]. 中华肾脏病杂志, 2023, 39(1):48-80. doi: 10.3760/cma.j.cn441217-20220630-00650
	Chinese Society of Nephrology. Guidelines for hypertension management in patients with chronic kidney disease in China (2023)[J]. Chin J Nephrol, 2023, 39(1):48-80. doi: 10.3760/cma.j.cn441217-20220630-00650

Stages	eGFR [mL/（min?1.73 m²）]	ICD-10
1	≥90	585.1
2	60-89	585.2
3	30-59	585.3
4	15-29	585.4
5	<15	585.5

Parameters	Hyperuricemic group （n=226）	Normal group （n=304）	Z/t/χ²	P
Sex, Male(%)	121（53.5）	107（41.8）	7.205	0.007
Age（years）	57.2（18.3）	53.9（17.6）	-2.059	0.040
BMI（kg/m²）	23.9（3.4）	22.7（3.6）	-3.925	<0.001
SBP(mmHg)	144（130-150）	130（120-130）	-7.862	<0.001
DBP(mmHg)	88（80-90）	75（70-80）	-7.231	<0.001
TG(mmol/L)	5.02（4.20-5.83	4.93（4.05-5.63）	-1.013	0.311
TC(mmol/L)	1.40（1.03-2.43	1.76（1.30-2.85）	-3.336	0.001
HDL-C(mmol/L)	1.23（1.01-1.51）	1.35（1.10-1.60）	-2.280	0.023
LDL-C(mmol/L)	2.77（2.22-3.58）	2.85（2.23-3.50）	-0.021	0.959
Creatinine(μmol/L)	132.0（95.0-228.3）	81.0(64.0-124.5)	-8.155	<0.001
Glucose(mmol/L)	6.8（5.1-8.9）	5.6（5.0-7.1）	-2.230	0.045

Uric acid quartile	Hypertension		χ²	P
Uric acid quartile	No	Yes	χ²	P
Q1	78（59.5）	53（40.5）	31.717	<0.001
Q2	52（38.8）	82（61.2）
Q3	47（35.6）	85（64.4）
Q4	33（24.8）	100（75.2）

UA	β	SE	χ²	OR(95%CI)	P
Q1			7.066	1.000	0.070
Q2	0.462	0.329	1.971	1.588（0.833-3.029）	0.160
Q3	0.314	0.351	0.798	1.368（0.687-2.724）	0.372
Q4	0.933	0.367	6.477	2.542（1.239-5.215）	0.011